Moderna's Covid Vaccine Sales Drop by Two-Thirds in 2023, Still Meet $6 Billion Forecast

Moderna's Covid vaccine sales dropped by two-thirds in 2023 to $6.7 billion, meeting the company's forecast, as demand waned with fewer people getting the updated jab. The revenue from the shots accounted for a significant portion of the company's overall revenue, but Moderna expects further decline in 2024. The company anticipates returning to sales growth in 2025 with the launch of new products and aims to "break even" by 2026.